Inderjit Mehmi

2.1k total citations
59 papers, 1.5k citations indexed

About

Inderjit Mehmi is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Inderjit Mehmi has authored 59 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 28 papers in Molecular Biology and 14 papers in Immunology. Recurrent topics in Inderjit Mehmi's work include Cancer Immunotherapy and Biomarkers (21 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (13 papers). Inderjit Mehmi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (13 papers). Inderjit Mehmi collaborates with scholars based in United States, Australia and Spain. Inderjit Mehmi's co-authors include Ruth Lupu, Javier A. Menéndez, Luciano Vellón, Rámón Colomer, David W. Griggs, Santiago Ropero, Poh K. Teng, Careen K. Tang, Miaw-Sheue Tsai and Ella Atlas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Inderjit Mehmi

54 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Inderjit Mehmi United States	19	972	556	544	179	114	59	1.5k
Sheng-Chieh Hsu Taiwan	16	1.0k 1.1×	811 1.5×	364 0.7×	151 0.8×	101 0.9×	16	1.7k
Qinghua Xiong United States	15	637 0.7×	515 0.9×	538 1.0×	192 1.1×	43 0.4×	20	1.3k
Alexei V. Salnikov Germany	17	870 0.9×	802 1.4×	433 0.8×	183 1.0×	121 1.1×	23	1.6k
Wei Jin China	23	1.0k 1.1×	577 1.0×	523 1.0×	182 1.0×	48 0.4×	72	1.7k
Nadine Rohwer Germany	18	805 0.8×	307 0.6×	666 1.2×	165 0.9×	36 0.3×	31	1.6k
Alexandra Grassian United States	12	1.2k 1.3×	367 0.7×	797 1.5×	106 0.6×	38 0.3×	17	1.7k
Chang Hun Rhee South Korea	22	968 1.0×	287 0.5×	405 0.7×	122 0.7×	110 1.0×	34	1.8k
Wendy J. Huss United States	22	981 1.0×	711 1.3×	497 0.9×	202 1.1×	66 0.6×	40	1.8k
Sébastien Jeay Switzerland	24	1.1k 1.2×	631 1.1×	320 0.6×	166 0.9×	47 0.4×	46	1.8k
Neil H. James United Kingdom	22	1.0k 1.0×	545 1.0×	303 0.6×	93 0.5×	42 0.4×	28	1.5k

Countries citing papers authored by Inderjit Mehmi

Since Specialization

Citations

This map shows the geographic impact of Inderjit Mehmi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inderjit Mehmi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inderjit Mehmi more than expected).

Fields of papers citing papers by Inderjit Mehmi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inderjit Mehmi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inderjit Mehmi. The network helps show where Inderjit Mehmi may publish in the future.

Co-authorship network of co-authors of Inderjit Mehmi

This figure shows the co-authorship network connecting the top 25 collaborators of Inderjit Mehmi. A scholar is included among the top collaborators of Inderjit Mehmi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inderjit Mehmi. Inderjit Mehmi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wehrenberg-Klee, Eric, Antoine Desîlets, Marlana Orloff, et al.. (2025). Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist. 30(10).

Weber, Jeffrey S., Amrutesh S. Puranik, Judith D. Goldberg, et al.. (2024). Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma.. Journal of Clinical Oncology. 42(16_suppl). 9538–9538. 10 indexed citations

Srkalović, Gordan, Michael Rothe, Pam K. Mangat, et al.. (2024). Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 8(8). e2400026–e2400026. 1 indexed citations

Weber, Jeffrey S., Waqas Haque, Svetomir N. Markovic, et al.. (2024). Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. The Oncologist. 30(3).

Sahai, Vaibhav, Michael Rothe, Pam K. Mangat, et al.. (2024). Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. 8(8). e2300527–e2300527.

Srkalović, Gordan, Michael Rothe, Pam K. Mangat, et al.. (2023). Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(16_suppl). 3115–3115.

Mileham, Kathryn F., Michael Rothe, Pam K. Mangat, et al.. (2023). Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 83(8_Supplement). CT226–CT226. 1 indexed citations

Weber, Jeffrey S., Waqar Haque, Svetomir N. Markovic, et al.. (2023). 1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma. Annals of Oncology. 34. S657–S658. 1 indexed citations

Patel, Sapna P., Meredith McKean, Alexander N. Shoushtari, et al.. (2023). 1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma. Annals of Oncology. 34. S677–S678. 2 indexed citations

10.

Dummer, Reinhard, Caroline Robert, Richard A. Scolyer, et al.. (2023). Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma. Cancer Research. 83(8_Supplement). CT002–CT002. 19 indexed citations

11.

Dimitriou, Florentia, J.C. Hassel, Marlana Orloff, et al.. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology. 33. S929–S929. 3 indexed citations

12.

Menéndez, Javier A., Adriana Papadimitropoulou, Elisabet Cuyàs, et al.. (2021). Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. Cancers. 13(5). 1132–1132. 33 indexed citations

13.

Patnaik, Amita, Inderjit Mehmi, James Strauss, et al.. (2021). 135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors. Annals of Oncology. 32. S1435–S1436. 6 indexed citations

14.

Hamid, Omid, Benedito A. Carneiro, Thomas U. Marron, et al.. (2021). 19O Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions. Annals of Oncology. 32. S9–S9. 12 indexed citations

15.

Mehmi, Inderjit & Omid Hamid. (2021). Immunotherapy of cancer in the era of checkpoint inhibitor. Clinical & Experimental Metastasis. 39(1). 231–237. 4 indexed citations

16.

Menéndez, Javier A., Inderjit Mehmi, Adriana Papadimitropoulou, et al.. (2020). Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. International Journal of Molecular Sciences. 21(20). 7661–7661. 23 indexed citations

17.

Ellis, Brian, et al.. (2017). Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report. International Journal of Ophthalmology. 10(7). 1183–1186. 29 indexed citations

18.

Alsharedi, Mohamed, et al.. (2015). Metastatic Sarcomatoid Carcinoma of the Small Intestine: a Case Report of Rare Tumor with Literature Review. Journal of Gastrointestinal Cancer. 47(4). 478–481. 3 indexed citations

19.

Salisbury, Travis B., Donald A. Primerano, Goran Bošković, et al.. (2014). Endogenous aryl hydrocarbon receptor promotes basal and inducible expression of tumor necrosis factor target genes in MCF-7 cancer cells. Biochemical Pharmacology. 91(3). 390–399. 23 indexed citations

20.

Lupu, Ruth, Inderjit Mehmi, Ella Atlas, et al.. (2003). Black cohosh, a menopausal remedy, does not have estrogenic activity and does not promote breast cancer cell growth. International Journal of Oncology. 23(5). 1407–12. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact